Related Experiment Video
Updated: Feb 13, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Anticoagulation use and clinical outcomes after catheter ablation in patients with persistent and longstanding
Jackson J Liang1, Melissa A Elafros2, Michael T Mullen3
1Cardiovascular Division, Electrophysiology Section, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Insights
Successful catheter ablation for atrial fibrillation (AF) may allow safe discontinuation of oral anticoagulation therapy (OAT) in selected patients, showing low rates of cerebrovascular events (CVEs). Further studies are needed to confirm safety after AF ablation.
Area of Science:
- Cardiology
- Electrophysiology
- Vascular Medicine
Background:
- Atrial fibrillation (AF) ablation success in reducing cerebrovascular events (CVEs) is debated.
- Safe discontinuation of oral anticoagulation therapy (OAT) after AF ablation remains unclear.
Purpose of the Study:
- Evaluate OAT use patterns post-ablation.
- Examine long-term rates of CVEs and major bleeding episodes (MBEs) in nonparoxysmal AF patients treated with catheter ablation.
Main Methods:
- Followed 400 patients with nonparoxysmal AF (persistent and longstanding persistent) for 3.6 years post-ablation.
- Permitted OAT discontinuation at physician discretion; analyzed AF recurrence, OAT status, CVEs, and MBEs.
- Used Cox regression to identify factors influencing OAT continuation and CVE risk.
Main Results:
- 43% of patients were free of AF recurrence; 43.5% were off OAT at last follow-up.
- No AF recurrence was linked to higher likelihood of OAT discontinuation (HR 0.23).
- CVE incidence was 0.49/100 patient-years; MBE incidence was 0.98/100 patient-years. Older age and CAD increased CVE risk.
Conclusions:
- Discontinuing OAT in selected, monitored patients post-successful nonparoxysmal AF ablation showed low CVE rates.
- Prospective research is essential to validate OAT discontinuation safety after AF ablation.
Introduction:
Whether successful catheter ablation for atrial fibrillation (AF) reduces risk of cerebrovascular events (CVEs) remains controversial and whether oral anticoagulation therapy (OAT) can be safely discontinued in patients rendered free of AF recurrences remains unknown. We evaluated OAT use patterns and examined long-term rates of CVEs (stroke/TIA) and major bleeding episodes (MBEs) in patients with nonparoxysmal AF treated with catheter ablation.
Methods And Results:
Four hundred patients with nonparoxysmal AF (200 persistent, 200 longstanding persistent; mean age 60.3 ± 9.7 years, 82% male) undergoing first AF ablation were followed for 3.6 ± 2.4 years. OAT discontinuation during follow-up was permitted in selected patients per physician discretion. At last follow-up, allowing for multiple ablations, 172 (43.0%) patients were free of AF recurrence. Two hundred and seven (51.8%) discontinued OAT at some point; 174 (43.5%) were off OAT at last follow-up. Patients without AF recurrence were more likely to remain off OAT (HR 0.23 [95% CI 0.17-0.33]). Patients with persistent (versus longstanding persistent) AF type prior to ablation (HR 0.6 [CI 0.44-0.83]) and those with CHA2 DS2 -VASc score <2 (HR 0.56 [0.39-0.80]) were less likely to continue OAT. Seven patients had CVEs (incidence: 0.49/100 patient years) and 14 experienced MBE during follow-up (incidence: 0.98/100 patient years). Older age (P = 0.001) and coronary artery disease (P = 0.028) were associated with CVE.
Conclusion:
Anticoagulation discontinuation in well selected, closely monitored patients following successful ablation of nonparoxysmal AF was associated with a low rate of clinical embolic CVEs. Prospective studies are required to confirm safety of OAT discontinuation after successful AF ablation.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...

